For: | Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol 2012; 18(35): 4823-4854 [PMID: 23002356 DOI: 10.3748/wjg.v18.i35.4823] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v18/i35/4823.htm |
Number | Citing Articles |
1 |
Ian Brown, Marian Priyanthi Kumarasinghe. Granulomas in the gastrointestinal tract: deciphering the Pandora’s box. Virchows Archiv 2018; 472(1): 3 doi: 10.1007/s00428-017-2210-3
|
2 |
Joo Hye Song, Sung Noh Hong, Jung Eun Lee, Kyunga Kim, Tae Jun Kim, Eun Ran Kim, Dong Kyung Chang, Young-Ho Kim. C-Reactive protein reduction rate following initiation of anti-tumor necrosis factor α induction therapy predicts secondary loss of response in patients with Crohn's disease. Scandinavian Journal of Gastroenterology 2019; 54(7): 876 doi: 10.1080/00365521.2019.1638962
|
3 |
Mohamad Abbass, Jeremy Cepek, Claire E Parker, Tran M Nguyen, John K MacDonald, Brian G Feagan, Reena Khanna, Vipul Jairath. Adalimumab for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2019; 2019(11) doi: 10.1002/14651858.CD012878.pub2
|
4 |
Yeonsil Yu, Eun Mi Song, Ko Eun Lee, Yang-Hee Joo, Seong-Eun Kim, Chang Mo Moon, Ha Yeong Kim, Sung-Ae Jung, Inho Jo, Hossam M. M. Arafa. Therapeutic potential of tonsil-derived mesenchymal stem cells in dextran sulfate sodium-induced experimental murine colitis. PLOS ONE 2017; 12(8): e0183141 doi: 10.1371/journal.pone.0183141
|
5 |
Mohamad Abbass, Jeremy Cepek, Claire E Parker, Tran M Nguyen, John K MacDonald, Brian G Feagan, Reena Khanna, Vipul Jairath. Adalimumab for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2017; doi: 10.1002/14651858.CD012878
|
6 |
Haimavati Rammohan, C. Ganesh Pai. Shrinking Indications for Azathioprine in Crohn's Disease: A Conclusion too Premature?. Gastroenterology 2014; 146(3): 866 doi: 10.1053/j.gastro.2013.10.071
|
7 |
Michele D. Mignogna, Stefania Leuci. Contemporary Oral Medicine. 2019; : 67 doi: 10.1007/978-3-319-72303-7_9
|
8 |
Ana Echarri, Virginia Ollero, Manuel Barreiro-de Acosta, Alberto Fernández-Villaverde, Vicent Hernández, Aurelio Lorenzo, Santos Pereira, Daniel Carpio, Javier Castro. Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naive Crohn’s disease. European Journal of Gastroenterology & Hepatology 2015; 27(4): 430 doi: 10.1097/MEG.0000000000000296
|
9 |
Antonio Speciale, Claudia Muscarà, Maria Sofia Molonia, Giovanni Toscano, Francesco Cimino, Antonella Saija. In Vitro Protective Effects of a Standardized Extract From Cynara Cardunculus L. Leaves Against TNF-α-Induced Intestinal Inflammation. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.809938
|
10 |
Alaa S. Awad, Hanning You, Ting Gao, Timothy K. Cooper, Sergei A. Nedospasov, Jean Vacher, Patrick F. Wilkinson, Francis X. Farrell, W. Brian Reeves. Macrophage-derived tumor necrosis factor-α mediates diabetic renal injury. Kidney International 2015; 88(4): 722 doi: 10.1038/ki.2015.162
|
11 |
Daniela Graf, Jennifer M. Monk, Wenqing Wu, Hannah R. Wellings, Lindsay E. Robinson, Krista A. Power. Red lentil supplementation reduces the severity of dextran sodium sulfate-induced colitis in C57BL/6 male mice. Journal of Functional Foods 2020; 64: 103625 doi: 10.1016/j.jff.2019.103625
|
12 |
Yoo Min Lee, Ben Kang, Yoon Lee, Mi Jin Kim, Yon Ho Choe. Infliximab “Top‐Down” Strategy is Superior to “Step‐Up” in Maintaining Long‐Term Remission in the Treatment of Pediatric Crohn Disease. Journal of Pediatric Gastroenterology and Nutrition 2015; 60(6): 737 doi: 10.1097/MPG.0000000000000711
|
13 |
Geert D'Haens, William J Sandborn, Jean Frederic Colombel, Paul Rutgeerts, Kurt Brown, Hadas Barkay, Anat Sakov, Asi Haviv, Brian G Feagan. A phase II study of laquinimod in Crohn's disease. Gut 2015; 64(8): 1227 doi: 10.1136/gutjnl-2014-307118
|
14 |
Nelson Carrillo. Gallbladder Polyps, Surgical Indications According to their Size and Morphology. Gastroenterology & Hepatology : Open Access 2015; 2(2) doi: 10.15406/ghoa.2015.02.00035
|
15 |
Jun-Seop Shin, Jung-Sik Kim, Jong-Min Kim, Jae-Yool Jang, Yong-Hee Kim, Hyun-Je Kim, Chung-Gyu Park. Minimizing Immunosuppression in Islet Xenotransplantation. Immunotherapy 2014; 6(4): 419 doi: 10.2217/imt.14.14
|
16 |
Angelo V. Marzano, Alessandro Borghi, Pier Luigi Meroni, Carlo Crosti, Massimo Cugno. Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy. Autoimmunity 2014; 47(3): 146 doi: 10.3109/08916934.2013.873414
|
17 |
Carlos S.M. Bezerra-Filho, Joice N. Barboza, Marilia T.S. Souza, Peter Sabry, Nasser S.M. Ismail, Damião P. de Sousa. Therapeutic Potential of Vanillin and its Main Metabolites to Regulate the Inflammatory Response and Oxidative Stress. Mini-Reviews in Medicinal Chemistry 2019; 19(20): 1681 doi: 10.2174/1389557519666190312164355
|
18 |
Michele D. Mignogna, Stefania Leuci. Contemporary Oral Medicine. 2018; : 1 doi: 10.1007/978-3-319-28100-1_9-1
|
19 |
Sang Hyoung Park, Young-Ho Kim, Ji Hyun Lee, Hyeok Jin Kwon, Suck-Ho Lee, Dong Il Park, Hyung Kil Kim, Jae Hee Cheon, Jong Pil Im, You Sun Kim, Sung Young Lee, Sang Joon Lee. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Review of Gastroenterology & Hepatology 2015; 9(sup1): 35 doi: 10.1586/17474124.2015.1091309
|
20 |
Ting Zhang, Qian-Yun Lin, Jia-Xi Fei, Yan Zhang, Min-Yi Lin, Shuang-Hong Jiang, Pu Wang, Ye Chen. Clostridium Difficile Infection Worsen Outcome of Hospitalized Patients with Inflammatory Bowel Disease. Scientific Reports 2016; 6(1) doi: 10.1038/srep29791
|